1. Home
  2. BKTI vs AKBA Comparison

BKTI vs AKBA Comparison

Compare BKTI & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BK Technologies Corporation

BKTI

BK Technologies Corporation

HOLD

Current Price

$83.50

Market Cap

326.9M

Sector

Technology

ML Signal

HOLD

Logo Akebia Therapeutics Inc.

AKBA

Akebia Therapeutics Inc.

HOLD

Current Price

$1.06

Market Cap

375.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BKTI
AKBA
Founded
1997
2007
Country
United States
United States
Employees
120
N/A
Industry
Radio And Television Broadcasting And Communications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
326.9M
375.0M
IPO Year
2000
2014

Fundamental Metrics

Financial Performance
Metric
BKTI
AKBA
Price
$83.50
$1.06
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
3
Target Price
$74.00
$4.67
AVG Volume (30 Days)
25.7K
4.7M
Earning Date
05-07-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
52.89
93.94
EPS
0.69
N/A
Revenue
$74,094,000.00
N/A
Revenue This Year
$6.57
N/A
Revenue Next Year
$15.00
N/A
P/E Ratio
$121.23
N/A
Revenue Growth
45.42
N/A
52 Week Low
$36.17
$0.88
52 Week High
$104.55
$4.08

Technical Indicators

Market Signals
Indicator
BKTI
AKBA
Relative Strength Index (RSI) 42.23 38.81
Support Level $73.47 N/A
Resistance Level $87.21 $1.56
Average True Range (ATR) 4.76 0.09
MACD -1.30 -0.03
Stochastic Oscillator 32.80 27.82

Price Performance

Historical Comparison
BKTI
AKBA

About BKTI BK Technologies Corporation

BK Technologies Corp is a holding company that, through BK Technologies, Inc., its operating subsidiary, provides public safety-grade communications products and services designed to make first responders safer and more efficient. All operating activities described herein are undertaken by its operating subsidiary. The Company has one reportable segment - Land Mobile Radio (LMR) Products and Solutions. The LMR segment provides radio devices that are hand-held (portable) or installed in vehicles (mobile) and operate on private radio systems that are P25 compliant. The Company derives revenue in North America and manages the business activities on a consolidated basis.

About AKBA Akebia Therapeutics Inc.

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.

Share on Social Networks: